SCB 313

Drug Profile

SCB 313

Alternative Names: Apo2L - Clover Biopharmaceuticals; SCB-313

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant ascites

Most Recent Events

  • 28 Dec 2017 Clover Biopharmaceuticals plans a phase I trial for Malignant ascites in Australia in March 2018 (NCT03443674) (Trial profile 700293417)
  • 28 Dec 2017 Clover Biopharmaceuticals in-licenses Trimer-Tag© technology from GenHunter Corporation worldwide (Clover Biopharmaceuticals website, December 2017)
  • 28 Dec 2017 GenHunter Corporation has patent protection for Trimer-Tag© technology in USA, Europe, Japan and China (GenHunter Corporation website, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top